Clot Management in the IVC: Matching the Device to the Disease

© 2026 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Vascular Disease Management or HMP Global, their employees, and affiliates.

During a Wednesday afternoon session at ISET 2026, William Kuo, MD, FSIR, of Stanford University School of Medicine, walked attendees through a practical, case-based approach to managing inferior vena cava (IVC) thrombosis. He emphasized that although IVC thrombosis is relatively uncommon, it carries outsized clinical consequences, with higher risks of pulmonary embolism, post-thrombotic syndrome, exercise intolerance, and long-term anticoagulation dependence than lower-extremity deep vein thrombosis alone.

Dr Kuo began by framing IVC thrombosis as a disease frequently driven by an underlying nidus, most often chronic indwelling IVC filters, congenital caval abnormalities, external compression, tumor thrombus, or prior caval trauma. He highlighted data showing that anticoagulation alone is often insufficient, particularly in filter-associated thrombosis, and underscored the important but sometimes underappreciated point that an IVC filter does not reliably protect against PE once acute caval thrombosis develops.

Dr Kuo spoke of the importance of decision-making around device selection and treatment strategy. With more than 70 thrombectomy and thrombolysis tools currently available, he emphasized that no single device fits every scenario. Instead, success depends on understanding clot chronicity, burden, and composition, as well as patient-specific bleeding risk and the presence of contraindications such as tumor thrombus, calcified or fibrotic clot, or fractured filters. He compared single-session mechanical approaches with overnight catheter-directed thrombolysis (CDT), noting that single-session therapy can reduce intensive care unit utilization and thrombolytic exposure but may increase access-site risk and procedural complexity while overnight CDT offers a lower-profile, staged strategy that allows time to address chronic disease at the cost of prolonged hospitalization and tPA exposure.

The presentation was anchored by multiple real-world cases illustrating tailored approaches to complex iliocaval disease. These included patients with acute PE despite therapeutic anticoagulation and indwelling filters, as well as elderly patients with debilitating symptoms refractory to anticoagulation alone. Across cases, Dr Kuo reinforced that clearing acute thrombus is only the first step; durable success depends on addressing the chronic nidus, often through advanced or off-label filter retrieval and selective caval revascularization, sometimes without the need for stenting.

In closing, Dr Kuo reminded attendees that aggressive mechanical thrombectomy carries real embolic risk, particularly in the setting of fibrotic clot or fractured filters, and that embolic protection should be considered in selected high-risk scenarios. His takeaway message was clear: effective IVC clot management is less about choosing the “best” device and more about choosing the right device and strategy for the specific pathology in front of you, with careful attention to both short-term safety and long-term venous outcomes.